![Elisa Agostinetto: A pooled analysis exploring tumor intrinsic subtypes in 3 trials on HER2+ EBC](https://oncodaily.com/pub/uploads/2024/02/download-29-e1710180869983.jpg)
Photo taken from Elisa Agostinetto/LinkedIn
Apr 3, 2024, 15:19
Elisa Agostinetto: A pooled analysis exploring tumor intrinsic subtypes in 3 trials on HER2+ EBC
Elisa Agostinetto, Research Physician at Institute of Jules Bordet in Brussels, posted on X/Twitter:
“Out in JAMA Oncology a pooled analysis exploring tumor intrinsic subtypes in 3 trials on HER2+ EBC.
pCR was associated with EFS in HER2-E and basal, but not luminal subtypes.
Benefit of dual HER2 blockade (T+L) was restricted to HER2-E tumors.”
View the article attached to the post.
Source: Elisa Agostinetto/X
Aug 29, 2024, 20:47